II. Indications
- See ACE Inhibitor
III. Mechanism
- See ACE Inhibitor
- Non-sulfhydryl Angiotensin Converting Enzyme (ACE) inhibitor
- Quinapril is a prodrug, converted to its active form Quinaprilat via hydrolysis
IV. Dosing
- Adequate 24 hour Blood Pressure control may require twice daily dosing
-
Hypertension
- Start 10 mg orally daily
- Start 2.5 to 5 mg orally daily in renal dysfunction or recurrent Diuretic use
- Target 20 to 40 mg/day
- Start 10 mg orally daily
-
Congestive Heart Failure (CHF)
- Start: 5 mg/day divided once to twice daily
- Titrate weekly to target 20 to 40 mg/day divided once to twice daily
- Low dose is especially important if concurrent Diuretic use
-
Renal Dosing
- GFR 30-60
- Start 5 mg orally daily
- GFR 10-30
- Start 2.5 mg orally daily
- GFR 30-60
- Maximum: 80 mg/day (no benefit above 40 mg/day)
V. Metabolism
- Excretion is 50-60% renal
VI. Supplied
- Available as generic scored tablets (5 mg) and unscored tablets (10,20 and 40 mg)
VII. Adverse Effects
- See ACE Inhibitor
VIII. Safety
- See ACE Inhibitor
- Pregnancy Category X
- Avoid in Lactation
IX. Resources
X. References
- (2016) Presc Lett, Resource #321151, ACE Inhibitor Antihypertensive Dose Comparison
- (2020) Med Lett Drugs Ther 62(1598): 73-80
- Olson (2020) Clinical Pharmacology, Medmaster Miami, p. 68-9
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
quinapril (on 2/23/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
QUINAPRIL 10 MG TABLET | Generic | $0.07 each |
QUINAPRIL 20 MG TABLET | Generic | $0.09 each |
QUINAPRIL 40 MG TABLET | Generic | $0.11 each |
QUINAPRIL 5 MG TABLET | Generic | $0.08 each |
QUINAPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB | Generic | $0.31 each |
QUINAPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB | Generic | $0.36 each |
QUINAPRIL-HYDROCHLOROTHIAZIDE 20-25 MG TAB | Generic | $0.34 each |
Ontology: quinapril (C0072857)
Definition (NCI) | A prodrug and non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Quinapril is hydrolized into its active form quinaprilat, which binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This abolishes the potent vasoconstrictive actions of angiotensin II and leads to vasodilatation. Quinapril also causes a decrease in angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis, and increases bradykinin levels. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C041125 |
SnomedCT | 108578004, 386874003 |
LNC | LP171631-7 |
English | 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, 3-Isoquinolinecarboxylic acid, 2-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-, monohydrochloride, (3S-(2(R*(R*)),3R*))-, quinapril, quinapril (medication), quinapril [Chemical/Ingredient], QUINAPRIL, Quinapril, Quinapril (product), Quinapril (substance) |
Spanish | quinaprilo, quinapril (producto), quinapril (sustancia), quinapril |
Ontology: Accupril (C0244580)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C041125 |
English | Accupril, accupril |